ERBB2 and breast carcinoma: Although patients included in our study did not have a record on hormone therapy and anti-HER2 therapy, most patients in our study received chemotherapy, and our results proved that the new AJCC breast cancer staging system could accurately evaluate the prognoses of these N3b patients.